ROUNDUP/Aktien New York Schluss: Dow mit zarter Erholung - Tech-​Werte schwächeln

Continuing to execute strategy on core focus

Donnerstag, 24.11.2016 12:21

Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.